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Abstract
Despite the discovery of antibiotics, the battle against bacteria is so far in their favor, spe-
cifically because bugs are able to develop a superstructure named biofilm, to resist and 
to survive in the environment. Nosocomial infections, a major health problem, are due 
at 80% to biofilm‐associated infection, and Staphylococcus aureus is the leading bacteria 
species in this domain. Moreover, the antimicrobial resistance of this bacterial commu-
nity is accentuated when it is formed by superbugs such as methicillin‐resistant S. aureus 
(MRSA). In this chapter, the mechanism and the physiology of S. aureus biofilm as well 
as their consequences in the clinical domains are described. To complete the vision on S. 
aureus biofilms, some “anti‐biofilm” strategies will be highlighted.
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1. Introduction
Discoveries in microbiology and the setup of aseptically processes in medical science allowed 
the possibility of high‐level surgery over the last century, with the hope of a safe healing. In 
return, major problems have appeared as nosocomial infections due to bacterial biofilm for-
mations on medical devices [1, 2]. Despite the multiplication of surgical procedures in order 
to get as close as sterile environment, bacterial contamination remains an important risk. 
Bacteria could indeed acquire antibiotic resistances and an emergence of multidrug resistant 
strains is observed [3, 4]. Moreover, the most alarming is that bacteria with regular sensitivity 
to antibiotics are even able to develop a strategy to survive: the formation of a strong com-
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munity named biofilm [1, 2, 5]. Biofilm‐associated infections represent 80% of nosocomial 
infections, and Staphylococcus aureus is the leading species in this domain [6–8].
Biofilm is defined as a multicellular lifestyle, an organized structure built by almost all bacte-
rial species. Even if the term “biofilm” has been used for more than 60 years, the understand-
ing of this structure started but recently. Fossilized biofilms of 3.5 billion years have been 
discovered and highlight the hypothesis that biofilm is a survival strategy always used by 
microorganisms since the dawn of time [5]. Scientists have recently understood that bacteria 
are not always living as free cells in nature; on the contrary, most of the time, bacteria build 
a real social life in a resistant community surrounded by a matrix composed of polysac-
charides, extracellular DNA, proteins, lipids and other components [1, 2]. Biofilm is present 
on biotic or abiotic surface and bacteria embedded inside are 10–1000 times more resistant 
to conventional antibiotics than free‐floating bacteria according to the strains, the molecule 
applied and the model of study [7–9]. Life cycle of biofilm is nowadays well‐described. 
First, bacteria adhere on a surface and they enhance different mechanisms to irreversibly be 
attached. Then, the program of biofilm starts with a maturation of the multicellular structure. 
To complete this cycle, dispersion of swimming cells occurs under specific conditions [1, 
2, 7–9]. However, the key of biofilm mechanism is the initiation that leads bacteria to form 
a biofilm and only under specific conditions. This trigger of biofilm mechanism is still an 
important question. Survival would be the answer, thus biofilm structure allows bacteria to 
resist to any types of environmental stress including UV, lack of nutrients and presence of 
antimicrobials [1, 2, 7–9].
All these characteristics lead to major problems in industries as well as in the medical domain. 
In industry, for example, the presence of multispecies biofilms has a high impact on the pro-
cesses or on the production and results in high costs. S. aureus can be isolated from biofilm 
found in food industry particularly in dairy process [10], and they are sanitizers resistant [11]. 
As a consequence, microorganisms can infect the milk or other food products and cleaning 
the production system is very complicated or impossible. Thus, all the structures need to be 
replaced representing an important waste of money.
In the medical domain, numerous difficulties to treat biofilm‐associated infections are 
described: resistance to antibiotics and to immune system, spread of infection, sepsis shock 
and surgical risks to remove infected implant or tissues [1, 6, 8]. S. aureus is one of the most 
frequent germs found in biofilm‐associated infections partially resulting from the fact that 
they are commensal bacteria on the human skin and mucous [12]. Moreover, S. aureus mul-
tidrug resistant like methicillin resistant S. aureus strains (MRSA), is responsible for biofilm 
infections that are more difficult to treat that need more intensive care and replacement of 
medical devices as compared to Staphylococcus epidermidis biofilm infections, for example. S. 
aureus also embodies an important reservoir of dissemination to other human body sites [12]. 
Consequently, the development of new therapeutic strategies, through a better understand-
ing of biofilms, is necessary and imperative [4] to fight against this structure resistant to the 
immune system and antimicrobial drugs.
Here after, to better understand the strength of S. aureus biofilms, different aspects relevant 
to biofilm, its mechanism and its physiology will highlight the aspects that are specific to 
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Staphylococci and S. aureus more precisely. The consequence of S. aureus in clinical domain 
will be described and some “anti‐biofilm” strategies will be suggested.
2. Biofilm life cycle
Different steps of biofilm life cycle have been well‐described through the study of different 
bacterial species: reversible adhesion, irreversible attachment, maturation and dispersion [5, 
13] (Figure 1). First, active bacteria can turn from “swimmers” to “stickers” on a support. A 
surface is supposed to always be in favor of adhesion because of the prediction that organic 
substances will concentrate on a surface and microorganisms will easily adhere and be pro-
tected from outsider challenges. Adhesion will dependent on the species of bacteria, sur-
face composition, environmental factors, and essential gene products [14]. Microorganisms 
could adhere on inert or biotic surfaces. Most of the time, interaction between bacteria and 
abiotic surface involves nonspecific interactions as opposed to active interaction between 
microorganisms and live tissues [14]. The surface conditioning is quite important through 
various physiochemical parameters: hydrophobicity, chemical composition of the material, 
surface energy, eletrostatic charges, temperature, surface roughness and in the case of biotic 
adhesion: serum and tissue protein adsorption [14, 15]. Hydrophobicity increases bacterial 
adhesion in most cases [15, 16]. In some environmental conditions, macromolecules adsorp-
tion could form a “film” neutralizing excessive charges and surface free‐energy facilitating 
bacteria and surface proximity. It was shown that pH parameters influence S. aureus adher-
ence on glass [17].
Figure 1. Biofilm life cycle.
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As far as S. epidermidis is concerned, Sousa et al. [15] have shown that surface conditions influ-
ence bacterial adhesion but the cell surface hydrophobicity itself was not linked to adhesion 
capacity, underlying the importance of other factors as cell wall associated proteins. The first 
bacteria approaching a surface adhere to it because of good conditioning but afterwards when 
the rate of cells increases, the following bacteria tend to adhere to previous bacteria instead of 
the surface [15]. In a case of a bad conditioning of surface and the necessity of adhesion, pili 
or other bacterial appendices could overcome potential repulsion.
2.1. Attachment on a surface
In any case, the life of a biofilm starts by an adhesion. The latter is reversible but can turn irre-
versible. Indeed, under specific conditions, events of irreversible attachment tend to increase 
and lead to the formation of a biofilm. In fact, irreversible attachment is the first step to the 
maturation of a future biofilm.
At the beginning, adhesion is the fortunate meeting between a good conditioned surface and 
a bacterium. In any environment, microorganisms can randomly get close to the surface or 
be attracted by chemotaxis involving their motility system [14]. Very recently, the ability for 
motility was observed for S. aureus even if they do not possess any appendages for movement 
[18]. This very particular movement is supposed to be a response to very specific conditions.
A surface could be attractive or repulsive for bacteria according to different parameters described 
above including hydrophobic and electrostatic interactions, hydrodynamic forces and tempera-
ture. Hydrophobicity is considered the most important. Bacteria could adhere on a biotic or abi-
otic surface thanks to the involvement of specific bacterial surface molecules such as the surface 
protein autolysin or the teichoic acids, altering the physicochemical properties of the bacterial 
surface rather than mediating the attachment via specific, receptor‐mediated interactions [13].
In the human body, S. aureus is known to have specific targets in relation with its pathogenesis. 
Staphylococci attachment to a biotic surface such as human tissue is due to specific interactions 
with its virulent factors (Figure 1). These bacteria possess a large variety of surface‐anchored 
proteins such as the microbial surface components recognizing adhesive matrix molecules 
(MSCRAMMS). MSCRAMMS are structured in three parts: a binding domain, a cell wall span-
ning domain and a third part responsible for the covalent or non‐covalent attachment of the 
MSCRAMM proteins on bacterial surface. These adhesins are able to bind to one or several dif-
ferent human matrix proteins (fibronectin, fibrogen, etc.) [13, 19, 20] and are required for biofilm‐
associated infections on indwelling medical devices covered by host matrix right after insertion 
[13]. Covalent bonds are catalyzed by sortases recognizing LPXTG motifs. S. aureus strains have a 
high variety of LPXTG‐type MSCRAMMs compared to S. epidermidis [21]. Other surface proteins 
involved in adhesion are Sdr proteins (Serin‐aspartate repeat family) or Aap (accumulation‐asso-
ciated proteins) [13]. Non‐covalently bounds are insured by other proteins such as the autolysin 
Atl. Autolysins, involved in cell wall turnover, are one of the most abundant proteins on the 
staphylococcal cell surface and possess binding sites for human matrix proteins [22, 23].
Staphylococci are known for their high ability to stick to plastic surfaces. Teichoic acids, which 
are not involved in S. aureus attachment on biotic surface, are important compounds present in 
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the cell wall and are important for adhesion on plastic surfaces thanks to their interaction with 
other surface polymers [13, 24]. However, in vitro assay over‐estimated the interactions between 
teichoic acids and devices mainly because devices in fluids or in tissue are rapidly covered by 
host matrix proteins preventing the direct interaction of teichoic acids to plastic. Despite teichoic 
acids, two other adhesins have a role for adherence on plastic: the cell wall bound surface pro-
tein Bap involved in adherence to polystyrene surfaces [25] and SasC a S. aureus surface protein 
involved in attachment on polystyrene that does not mediate binding to fibrinogen, thrombos-
pondin‐1, von Willebrand factor or platelets [26]. Also, autolysins facilitate attachment to plastic 
in addition of their capacity to bind to human matrix and their enzymatic function [23].
2.2. Communication between bacteria
Pseudomonas aeruginosa biofilm is one of the most studied biofilm models. A powerful sys-
tem of communication between cells was described in P. aeruginosa biofilm and named “quo-
rum‐sensing” [27]. First the quorum‐sensing system was linked to a communication based 
on cell density. Then, quorum‐sensing is virtually connected to biofilm formation and dis-
persal phenomena. The communication system in P. aeruginosa is based on molecules called 
acyl‐homoserine lactones (AHLs) which penetrate bacteria and directly regulate target genes. 
Quorum‐sensing systems have been described in Gram‐negative and Gram‐positive bacteria. 
Each quorum‐sensing system is composed with different molecules and can activate or inhibit 
biofilm formation. The most studied system in S. aureus is the Agr quorum‐sensing system 
but other systems of communication exist.
For S. aureus, only one specific quorum‐sensing system was so far described, but most prob-
ably, there are other mechanisms for communication. At some point, some genes involved 
in S. aureus virulence were named accessory genes, and an accessory gene regulator (agr) 
was identified as a global regulator of virulence factors genes. Different experimental designs 
have shown that the Agr system induced by an extracellular ligand, the autoinducing pep-
tides (AIP), is a sensor of population and so considered as a quorum‐sensing system. This 
system can be activated by addition of AIP or by glucose depletion [28]. Briefly, this system 
is composed of two promoters P2 and P3. P3 transcript encodes RNAIII, the intracellular 
effector of target gene regulation, answering to agr system activation. P2 operon encodes for a 
two‐component system and its autoinducing ligand AIP [29].
During biofilm formation, Agr quorum‐sensing system is repressed to stop the expression 
of S. aureus colonization factors [29], and it gets activated during the dispersion of the bac-
teria [30]. Artificial activation of Agr has also been shown to induce biofilm dispersion [28]. 
Moreover, Agr quorum‐sensing system is necessary for the communication inside mature 
biofilm to establish the 3D structure through the control of cell dispersion. This probably 
requires phenol‐soluble modulins (PSMs) which are described in the next section and pro-
teases activated by Agr and involved in the degradation of exopolysaccharides (EPS) matrix 
[31]. However, Agr does not control important biofilm adhesive molecules such as the poly-
saccharide intercellular adhesions, currently named PIA [32]. In conclusion, Agr system regu-
lation is based on cell density. During the early stage of colonization, cell density is low and 
as consequences Agr quorum‐sensing activity gets weak and the cell wall protein or surface 
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adhesins are not downregulated but highly expressed. In the later stage, Agr activity increases 
with cell density and thereafter Agr upregulates secreted virulence factors such as lipases, 
proteases and hemolysin [33]. Not surprisingly, Agr involvement in biofilm formation seems 
to be under specific environmental conditions as shown by the contradiction of experimental 
results relevant to the model used in the study [30]. One problem underlined each time is the 
difficulty to detect agr expression due to the very slow bacteria metabolism in the biofilm. 
During hospitalization, S. aureus strains isolated from patients are more frequently Agr‐defec-
tive strains showing their better ability to turn into a nosocomial infection agent [34]. Some 
agr‐defective mutants have been isolated from catheter infections, where they had the capac-
ity to form a compact biofilm with the loss of their capacity to detach and disseminate.
Other regulators have been identified such as Rbf which is involved in S. aureus biofilm for-
mation at the maturation stage rather than at the initial attachment [35]. This regulator did not 
affect ica gene locus coding for adhesins; however, a clinical isolate with rbf mutation showed 
a lower capacity to form biofilm. LuxS, another regulator first described in Vibrio cholerae, 
is under the control of the auto‐inducer AI‐2 and seems to play a role in biofilm formation 
through the icaR expression. However, LuxS is also involved in the S‐adenosyl methionine 
cycle, and its role in biofilm is consequently debated as it could be the result of this metabolic 
role [36].
In conclusion, production of surfactant molecules dependent of quorum‐sensing system 
appears to be a general mechanism for the biofilm structuring as well as for the detachment 
of many bacteria. In the specific S. aureus quorum‐sensing, biofilm is based on the detection of 
signaling molecules by specific sensors which lead to a chain reaction with different molecu-
lar actors and not on a direct communication where the signal molecules enter in the cells 
and directly regulate different genes. In S. aureus, the sensors are numerous and allow a fast 
answer of the bacteria.
2.3. Maturation
The maturation of biofilm is based on the development of the multicellular structure (Figure 1). 
Biofilm growth is controlled by the increase of bacterial mediators, the slowdown of metabo-
lism and cell cooperation. Maturation starts when bacterial cells induce the biofilm program 
and create an intercellular aggregation through the production of a “slime” commonly named 
matrix. The latter sticks bacteria one to each other as well as on surface. The matrix is com-
posed of exopolysaccharides (EPS), proteins and extracellular DNA (eDNA) and is respon-
sible for biofilm maturation that is the result of an organized community construction. This 
specific 3‐dimensional structure appears as a typical mushroom‐like shape containing water 
or fluid channels formed thanks to a disruptive process [37]. Paradoxically, maturation in the 
construction of the community needs also disruption events. Fluid‐filled channels are vital in 
delivering nutrient into biofilm deeper layers [38]. This kind of structure is species‐specific.
Exopolysaccharides are the first molecules discovered in biofilm matrix. In staphylococci, the 
most described adhesive biofilm molecule is the polysaccharide intercellular adhesion (PIA) 
or poly‐N‐acetylglucosamine (PNAG) and represents the major part of the staphylococci bio-
film‐forming extracellular matrix [39]. PIA has an important role in the biofilm structure and 
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the biofilm‐associated infections [40, 41]. Introducing a positive charge in the environment of 
the bacterial cell surface which is negatively charged, PIA works like a glue sticking the cells 
together by electrostatic interaction [42]. PIA is encoded by ica gene locus and regulated by 
numerous environmental factors [43]. For example, SarA and SigB upregulate PIA expression 
and on the contrary LuxS downregulates it [44–46]. PIA is the only factor identified so far as 
important for staphylococci biofilm formation in vivo [13, 43]; however, PIA is not present in 
all strains isolated from biofilm‐associated infections [47]. Therefore, some other compounds 
like proteins must also play a role.
Numerous specific proteins could be substitute for PIA in biofilm formation as proteins are 
now recognized as essential for biofilm structure, such as the following proteins: Aap (accu-
mulation associated protein), extracellular matrix binding protein (Embp), protein A, fibrino-
gen‐binding proteins (FnbpA and FnbpB) or S. aureus surface protein G (SasG) [48]. This latter 
mediates intercellular aggregation thanks to hydrophilic interaction with the proteins present 
on other bacteria [49]. As for S. aureus surface protein SasC, which possesses a LPXTG‐motif 
to anchor to cell wall, it is involved in intercellular aggregation and biofilm maturation [26]. 
Depending on the Staphylococcus, the extracellular Aap protein [50] is involved in PIA‐inde-
pendent biofilm formation in S. epidermidis [51] or in the maturation of the biofilm by interac-
tions with PIA like in S. aureus [50].
All these results underline the importance of the surfactants in biofilm maturation. Phenol‐
soluble modulins (PSM) are surfactant peptides found in both S. aureus and S. epidermidis. 
Their sequence is species dependant, but they all have an amphipathic α‐helix [13]. PSMs are 
strictly controlled by Agr, with a direct binding of Agr regulator on the psm operon promoter, 
suggesting that Agr‐dependent biofilm maturation processes are due to PSMs expression [13]. 
Moreover, an agr mutant strain of S. aureus has the same behavior that a completely deleted 
PSM genes mutant in in vivo model [13]. As shown in S. epidermidis, the PSM involvement 
in biofilm maturation is independent of the PIA protein. In S. epidermidis, the lack of PSMs 
leads to biofilms that are more “compact”, suggesting that PSM are also involved In biofilm 
 development. Furthermore, as seen in all the Staphylococcus, the presence of the PSM peptides 
is needed for biofilm volume, thickness, roughness and channel formation [52]. Surfactant 
peptides are therefore the key of the 3‐dimensional biofilm structure. PSMs also induce bio-
film detachment [52] and are biofilm maturation in vivo determinant factors [13].
Amyloid proteins have also been revealed as important for biofilm structure, bringing stabil-
ity to the matrix [53]. These protein fibers could bind the extracellular DNA. PSMs play also 
a role as inert fibrils in biofilm, acting as a solid bond, waiting for better conditions to induce 
their dissociation and promote biofilm dispersion [53, 54]. Bap another cell wall bound sur-
face protein [25, 55–57], involved in adhesion, is also required for biofilm maturation and 
infection of bovine mammary glands [20, 45]. This protein is a real sensor, responding to envi-
ronmental conditions (like calcium concentration), and Bap is also a scaffold protein forming 
amyloid‐like aggregates at low calcium concentration and under acidic pH [53].
Under an organized construction, biofilm maturation is based on development and disrup-
tion events. Thus, PIA‐degrading enzymes (PIAse) are supposed to contribute to biofilm mat-
urating but they have never been found in staphylococci [13]. Anyway other proteases could 
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have an important role in staphylococci biofilm maturation as proven by strains showing 
PIA‐independent biofilm formation [58]. Those proteases are regulated mostly by SarA and 
more rarely by Agr, but so far no experiments have demonstrated direct evidence for their 
role on biofilm development or protease‐mediated biofilm detachment.
The third important element of matrix composition is extracellular DNA (eDNA). DNA, a 
polyanionic molecule present in biofilm matrix, is described as a ligand able to link to other 
molecules present in the matrix such as teichoic acids or PIA. Therefore, DNA has a role in 
biofilm structure. This presence is based on the involvement of cell death: DNA released 
from lysed bacteria also called eDNA has a critical involvement during initial attachment and 
maturation. An increase of cell lysis influences biofilm formation through the Cid proteins 
[59–61]. Indeed, regulators like CidR which controls autolysis are involved in biofilm devel-
opment and the formation of the tower mushrooms shapes [62]. Extracellular DNA appears 
through the bacterial programmed cell death and through the expression of cidA gene encod-
ing for a holin responsible for lysis. This system is regulated by the production of an antiholin 
encoded by lrgAB genes which is an inhibitor of cidA‐mediated lysis [59, 62]. However, in 
vivo, the importance of eDNA is difficult to assess as well as to understand how a staphylo-
coccal biofilm could survive in the presence of human DNAseI which succeed to disperse a 
mature biofilm in vitro [13].
In conclusion, scientists have realized how important it is to have precise knowledge of the 
mechanisms involved in the biofilm extend matrix or in the detachment steps to be able to 
develop anti‐biofilm strategies. However, biofilms are also formed by four set of cells: some 
with an aerobic or fermentative growth, some dormant or dead [63]. This cell heterogeneity 
within the biofilms has to be kept in mind in the search of anti‐biofilm therapy.
2.4. Dispersion
Disruptive processes are vital for biofilm structure and disruption allows the detachment of 
single cells or large bacteria cluster from biofilm in case of good environmental conditions or 
in case of expansion of the biofilm (Figure 1). This dispersion has important consequences in 
biofilm‐associated infections as it leads to systemic dissemination. It is well known now that 
detached cells from biofilm could lead to endocarditis or sepsis [13].
Disruption is based on mechanical forces as well as the interruption of the production of the 
biofilm material and production of enzymes and surfactants that are considered as detachment 
factors able to destroy the matrix. Agr quorum‐sensing system involved in biofilm formation 
and extracellular protease activity are required to control biofilm dispersal molecules [28, 32, 
52]. Expression of agr mostly carried out by the bacteria in the outer layers of the biofilm leads 
to detachment and regrowth [30], but agr is also expressed in deeper layers where it is required 
for channel formations [52]. In fact this dispersal effect linked to Agr system could be due to the 
involvement of PSMs whose expression is controlled by the Agr quorum‐sensing.
Nucleases, the enzymes degrading extracellular DNA are also necessary. The human DNaseI 
degrades staphylococcal biofilms [64]. Staphylococcal thermonuclease nuc2 is involved in the 
biofilm development probably to promote dispersion [65]. A second nuclease nuc1 showed 
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the similar dispersal effect as nuc2 on biofilm in vitro [66]. Nevertheless, those effects are not 
detected so far in in vivo models [66].
Other factors, involved in dispersion, have been described such as bacteriophages which have 
been revealed as important for biofilm development, especially in dispersal stage [31]. Even 
proteases like Aur metalloprotease and Slp serine protease have been shown to be responsible 
of dispersal movement [67].
In conclusion, biofilm life cycle starts under the impulse of a stress response (e.g., starvation) 
and bacteria attach on a surface where cell proliferation is more favorable. A monolayer is 
formed, and some specific genes are expressed inducing the production of microcolonies. 
Quorum‐sensing system acts as a supervisor, and biofilm is formed in a well‐organized 
structure.
3. Physiology of biofilm
Biofilms seem to be the best strategy for bacteria to survive to any kind of environmental 
stress. The detection of stress and thus the response needs to be fast enough to survive under 
those conditions. Therefore, the rapid process of activation of the biofilm program is crucial 
for the bacteria.
3.1. Program on/off
As described for stress response, the setup of inducible processes is based on the differential 
expression of an important number of genes [68, 69]. Biofilm bacteria cells are physiologi-
cally different from free cells [12]. Indeed, the different steps as adhesion and immobilization 
need the expression of various genes. More important, the communication between bacteria 
(quorum‐sensing system) controls many metabolic systems and leads to regulation of many 
genes. The production of the quorum‐sensing molecules as an endogenous signal leads to 
changes according to the detected concentration. Environmental clues trigger genetic and 
physiological changes also called biofilm transition. As previously described, the matrix is the 
plinth of biofilm development and is responsible for many processes in the biofilm program. 
Moreover, biofilm cells show a general downregulation of their metabolism underlining the 
slow growing cell or the lack of oxygen due to the biofilm structure, like during fermentation. 
An upregulation of the urease and the arginine deiminase pathway to limit the side effects 
of the acidic pH during anaerobic growth was also observed in biofilm structure [12]. All 
those adaptations participate to a general biofilm setup process. The differential gene expres-
sions also lead to antibiotic resistance mechanism. In S. epidermidis, some of these antibiotic 
resistance mechanisms are upregulated during biofilm stage [70]. In S. aureus, Agr expression 
and involvement in biofilm formation depend of the environmental conditions [30]. The agr 
expression shut down has no effect, enhances or inhibits biofilm formation according to the 
environmental parameters [30].
Biofilm program is a temporary response to stress conditions and this process is able to turn 
off quite quickly when conditions are more favorable for the bacteria.
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3.2. Interactions with the environment and survival strategy
Bacteria have the extraordinary ability to survive in any harsh conditions, and as recently discov-
ered, this is due to their capacity to form biofilm. Many environments can be a source of stress 
for bacteria. S. aureus biofilm have been found in industry and in clinical domain, particularly in 
biofilm‐associated infections. Environmental stresses are supposed to induce biofilm formation. 
As evidence, sigma B, a protein required for transcription and activated under stress responses 
due to heat shock, MnCl
2
, NaCl
2
 and alkaline shock, is involved in biofilm formation [71, 72].
In S. aureus, nutrients like glucose or NaCl can influence biofilm. For example, Rbf regulator is 
involved in biofilm formation under high concentrations of glucose and NaCl conditions, but 
not in the presence of ethanol [35]. Nutrient‐starvation has been underlined as an important 
environmental stress which could induce biofilm maturation [61, 73]. In vitro, however, the 
addition of glucose is required for biofilm formation and activation of the agr quorum‐sensing 
system [28], even if oldest results showed the contrary [74]. In fact, conditions to form biofilm 
seem to be very specific, such as a balance between an over‐concentration of glucose and a 
lack of carbon source. The pH maintenance also influences Agr system and, in consequence, 
probably acts on biofilm formation [74, 75].
Nitrite stress also induces PIA expression, responsible for the major part of the matrix com-
position [76]. In fact, induction or repression of biofilm formation is due to a balance of con-
centration of specific nutrients or stress. For example, NO is necessary for biofilm formation 
until its concentration starts to be too high. Thereafter, NO is involved in the dispersion of the 
biofilm [77]. It has also been observed that low oxygen, even anaerobic state, like in the heart 
of the biofilm, increases PIA expression [78].
In human body, the lack of nutrients (e.g., iron, carbon source, etc.) or oxygen, the presence of 
the immune system or even the antimicrobial molecules are felt by the bacteria as stresses and 
could induce biofilm program. In S. aureus, PIA expression and biofilm maturation are strongly 
inducible by conditions found in vivo as described in a device‐related infection model [79]. 
In S. epidermidis, subinhibitory concentrations of tetracycline and quinupristin ‐  dalfopristin 
induce ica gene cluster expression and the increase of Mg2+ concentrations increase biofilm pro-
duction. On the contrary, the addition of  EDTA (Ethylenediaminetetraacetic acid) decreases 
the number of cells on a plastic surface [14]. Zinc concentration might also influence bio-
film adhesion through the  activity of SasG a surface protein with zinc‐dependent mechanical 
properties [49]. Subinhibitory concentrations of furanone, molecules isolated from red algae, 
inhibit quorum sensing but also favor biofilm formation [80, 81]. This result reflects the pos-
sible inter‐species interaction domain and the importance of the specific microenvironment.
In nature, many bacteria live under nutrient‐limited conditions, lack of oxygen and under 
many other dangers like humidity, osmotic pressure and mechanical forces. Biofilm through 
the presence of the matrix protect all the embedded bacteria from all those environmental 
variations and pressures.
3.3. Interactions with the host immune cells
During bacterial infection, host immune cells are the defenders of the organism. Through 
mechanisms such as phagocytosis or release of bactericidal components, these cells are able 
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to fight and neutralize planktonic S. aureus. Concerning S. aureus biofilm, the general thought 
is that biofilm structure protects the bacteria against the immune cells, avoiding interaction 
between both actors. Nevertheless, recent studies reported that polymorphonuclear neutro-
phils (PMN), macrophages, myeloid‐derived suppressor cells (MDSCs) and T lymphocytes 
can interact with S. aureus biofilm in a double‐edged interplay (Figure 2).
PMNs are the first line of defense in bacterial infections. These cells can phagocyte planktonic 
bacteria and release bactericidal components such as reactive oxygen species or enzymes 
[82]. Contrary to the dogma, in vitro experiments revealed that PMN can also attack S. aureus 
in biofilm form. PMNs can migrate towards and into the S. aureus biofilm and clear it by 
phagocytosis. The extent of biofilm clearance is apparently depended on its maturation state. 
Indeed, mature biofilms were reported as more resistant to phagocytosis as young ones [83]. 
Following phagocytosis, PMNs underwent apoptosis, a programmed cell‐death in order to 
prevent spilling of the bactericidal and cytotoxic entities [84]. In addition to phagocytosis, 
PMNs can release lactoferrin and elastase through degranulation phenomenon, as well as 
DNA [85]. Oxygen radical production by the PMNs also participates to biofilm clearance and 
is depended on the coating of biofilms with IgG, a mechanism termed “opsonization” [86]. In 
a global manner, PMNs can be considered as an asset to fight against S. aureus biofilms.
In parallel to PMNs response, a macrophage response is also triggered during S. aureus infec-
tions, which is altered in case of S. aureus biofilm infection. Indeed, planktonic S. aureus nor-
mally induces a proinflammatory microbicidal phenotype in macrophages defined as M1. It 
implies the phagocytosis of bacteria and the production of bactericidal components [87]. In 
the context of S. aureus biofilm infection, in vitro and in vivo studies reported that invasion 
of macrophages into biofilms is limited. S. aureus biofilms is able to secrete specific toxins 
Figure 2. Interplay between S. aureus biofilm and host immune cells.
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called alpha‐toxin (Hla) and leukocidin AB (LukAB) that inhibit macrophage phagocytosis 
and induce cytotoxicity, promoting macrophage dysfunction and thus facilitating S. aureus 
biofilm development [88]. Moreover, S. aureus biofilm can also induce the polarization of mac-
rophages from a proinflammatory microbicidal M1 phenotype to an alternatively activated 
M2 phenotype, displaying anti‐inflammatory properties and limited phagocytosis [33, 89]. A 
recent study showed that the treatment of established biofilm infections with M1‐activated 
significantly reduced biofilm burdens, supporting that M1 phenotype is unpropitious to S. 
aureus biofilm development whereas M2 polarization favors it [90].
The most recent studies concerning interactions between S. aureus biofilms and immune cells 
focus on the MDSCs, a heterogeneous population of immature monocytes and granulocytes 
with immunosuppressive properties. In case of S. aureus biofilm infection, MDSCs prevent 
monocyte/macrophage pro‐inflammatory activity, inhibit T lymphocytes proliferation and 
facilitates biofilm persistence [91]. This phenomenon is in part orchestrated by the interleu-
kins IL‐12 and IL‐10 [92, 93]. IL‐12 is a cytokine with both pro‐ and anti‐inflammatory proper-
ties that promotes the recruitment of MDSCs whereas IL‐10 is an anti‐inflammatory cytokine, 
mainly produced by MDSCs in context of biofilm infection. A recent study reported that IL‐10 
promotes biofilm growth and anti‐inflammatory gene expression in monocytes, which can 
be assimilated to a polarization to M2 phenotype [93]. MDSCs would in the end be the effec-
tors for the development of the anti‐inflammatory environment that favors S. aureus biofilm 
persistence.
Concerning interactions between S. aureus biofilm and T lymphocytes, Leid et al. reported that 
mononuclear leukocytes, especially lymphocytes and in a lesser extend monocytes, can attach 
to the biofilm but they are not able to phagocyte maturing and fully matured S. aureus biofilm 
[94]. In case of S. aureus biofilm infection, early Th1 and Th17 inflammatory responses are 
increased and Th2 as well as Treg responses seem downregulated [95]. Th2/Treg responses 
appear as a protection mechanism for the organism as opposed to Th1/Th17 responses, which 
may favor the development of chronic S. aureus biofilm infection [96]. This response, in oppo-
sition to what is observed in the macrophage response, reveals the complexity of the interac-
tions between S. aureus biofilms and the cells of the immune system.
4. S. aureus biofilm‐associated infections and antibiotic treatments
4.1. S. aureus biofilms are responsible for different types of infection
Different bacteria are involved in infections associated with biofilm development in immu-
nocompromised patients or medical devices. Sadly, the most famous example is P. aeruginosa 
species which develop highly resistant biofilm in pulmonary tract of cystic fibrosis patients.
Biofilm formation is linked to various staphylococcal diseases such as endocarditis, osteo-
myelitis, skin and soft tissues infections, urinary tract infection, nasal colonization and cys-
tic fibrosis complications as well as implant‐associated infections [97–99]. In most of the 
case, the production of biofilm favors the chronicity of S. aureus infections. The coloniza-
tion of implanted materials by staphylococcal biofilm is one of the highest important issues. 
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Staphylococcal biofilm can develop on various structures such as catheters, prosthetic joints, 
prosthetic heart valves, contact lenses, cerebrospinal fluid shunts and cardiac pacemakers 
[100]. Furthermore, after their implantation in the body, medical devices become coated with 
host proteins, facilitating the attachment of S. aureus and the biofilm formation [101].
4.2. S. aureus biofilm‐associated infections are more resistant
Biofilms have shown unbreakable structures resistant to antibiotics and many other mole-
cules or environmental stresses. Many hypotheses have been tested to explain this incred-
ible natural invincibility. First, the intrinsic structure of biofilm supposes that antimicrobials 
could not penetrate inside the biofilm. This hypothesis has been revealed unlikely for most 
of the antibiotics as the biofilm structure is composed with many water channels. A second 
hypothesis is based on the fact that the biofilm matrix can accumulate antibiotic‐degrading 
enzymes, and in consequence, antibiotics are quickly destroyed [9]. Then, scientists underline 
the fact that microorganisms have a very slow metabolism in the biofilm preventing most of 
the kinetic responses involved in the antibiotic mechanism. The use of antibiotics targeting 
more specifically those slow growth bacteria was not more successful, even combined with 
antimicrobial drugs that could target active bacteria present in the biofilm population, known 
to be heterogenic [63]. Persister cells can also be present in this heterogeneous population and 
can withstand high concentration of antimicrobial drugs.
Nowadays, it seems that the natural resistance of biofilms comes from the induction of spe-
cific biofilm mechanisms [9]. Stress responses, as biofilm formation, lead to the changes of 
many gene expressions which increase the antimicrobial resistance. Nutrient starvations are 
now known to favor antibiotic tolerance [61].
Biofilm is the perfect example of an adaptive resistance, not due to a genetic mutation that 
could be transferred to daughter cells, even if the bacteria proximity in the biofilms increase 
horizontal transfer gene or mutation that could lead to intrinsic resistance [9].
4.3. Current treatment of S. aureus biofilm
Treatment of S. aureus biofilm is a therapeutic challenge. Even if everybody has in mind that 
the embedment of S. aureus in slime gives him an increased tolerance to antibiotics, two situ-
ations have to be defined concerning the treatment of S. aureus biofilm‐associated infections.
Firstly, antibiotics can have an inhibitive effect on the formation of biofilm. It is related to the 
capacity to inhibit the attachment and the initial growth of the biofilm. A recent study specifi-
cally evaluated the inhibition of S. aureus biofilm formation through the use of a new system 
the antibiofilmogram® [102]. Based on Biofilm Ring Test® method [103], this system permits to 
define, for a chosen antibiotic, the minimal inhibiting concentrations (MIC) needed to inhibit 
biofilm formation (called bMIC). In this study, Tasse et al. reported that the bMIC is equiva-
lent or close to the MIC for planktonic bacteria. Similar values between MIC and bMIC were 
notably observed for clindamycin, fusidic acid, linezolid and rifampin [102].
The second situation concerns the efficiency of antibiotics on formed/mature biofilm. The 
sessile community is already organized and persisters can be present. In this case, antibiotic 
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efficiency is defined through the measure of the minimal biofilm eliminating concentration 
(MBEC) via the use of the Calgary Biofilm Device [104]. MBEC for S. aureus biofilms can be 
10–1000 times higher than the MIC defined for planktonic bacteria, depending on the investi-
gated strains and antibiotics [105–108].
The difference between bMIC and MBEC is probably due to a lack of penetration/diffusion 
of antibiotics inside the biofilm, even if this statement still stays controverted. Indeed, a 
decreased penetration of antibiotics has been observed in in vitro models of S. aureus biofilm 
[109, 110]. The penetration inside biofilm varies depending on the type of antibiotics and the 
structure of the biofilm. On the contrary, other studies, such as the recent one by Boudjemaa et 
al. reported that the biofilm matrix was not a shield to the antibiotic diffusion. They observed 
that the concentration inside the biofilm is similar to the one that could be found outside the 
biofilm. In this case, the resistance to the treatment would be related to a decreased effect of 
the drug to S. aureus [98, 111]. An interesting compromise can be that several factors influence 
the efficiency of antibiotic treatment against S. aureus biofilm. Lack of penetration is one of 
them but cannot be the only answer by its own.
With regards to this, the combination of antibiotics appears as an interesting solution for 
an effective treatment. Susceptibility test revealed that rifampin, but also vancomycin and 
fusidic acid were the most interesting constituent of antibiotic combinations active against 
the staphylococcal biofilms [112]. In an innovative in vitro model, Parra‐ruiz et al. demon-
strated that the combination of daptomycin or moxifloxacin with clarithromycin is of greater 
effect than the individual effects of the three agents against a biofilm formed by a methicil-
lin‐sensible S. aureus (MSSA) strain. Similar observations were made for the combination of 
linezolid and daptomycin as well as for daptomycin and rifampicin against a MRSA strain 
[113, 114]. However, recent studies suggested that combination of antibiotics could also have 
an antagonistic effect on the elimination of S. aureus biofilm. It was reported that linezolid can 
antagonize vancomycin and daptomycin activities [115]. In an infective endocarditis model 
of biofilm‐forming MRSA, Laplante and Woodmansee observed that rifampin and genta-
micin antagonized or delayed the bactericidal activity of daptomycin and that daptomycin 
monotherapy had better in vitro activity than vancomycin‐containing combinations [116]. 
Moreover, according to Croes et al., the use of rifampin‐containing combinations against S. 
aureus biofilm remains unpredictable, ranging from a tendency toward antagonism to some 
synergism effects [117]. At the opposite, a recent study, analyzing the antibiotic susceptibility 
of 58 clinical isolates, emphasized that there are no evidence for advice against the daptomy-
cin/rifampin combination therapy for MSSA/MRSA infection.
The efficiency of antibiotic monotherapies or bi-therapies was most of the time evaluated 
through the use of in vitro models. In vivo models of infection are of high importance to com-
fort and strengthen the results between the bench and the patient bed. In a MRSA joint pros-
thesis rabbit infection model, the combination of rifampin with daptomycin was observed to 
be more effective than a treatment of either of these agents [118]. Similar results were reported 
about the combination of linezolid with rifampin or vancomycin with rifampin in a rabbit 
model of MRSA foreign body osteomyelitis [119]. Recently, study tested several antibiotics 
alone and in combination in a murine model of implant‐associated osteomyelitis. The authors 
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reported that the most effective antibiotic combinations contained rifampicin and that the 
combinations containing two nonrifampicin antibiotics were not more active than single 
drugs [120].
Globally, trying to prevent the biofilm formation appears as the most interesting way to fight 
this kind of infection. In case of full‐formed biofilm infections, using a combination of high‐
dosed antibiotics containing rifampicin and/or daptomycin seems to be the best option.
In addition to the difficulties to treat biofilm‐associated infection, there is also the important 
delay necessary to spot them. The emergency of finding a technical approach to detect biofilm 
in the analysis laboratories is huge. Some biomarkers have been searched, especially thanks 
to qPCR (quantitative polymerase chain reaction) techniques. For example, ica genes encoding 
for PIA can be identified by PCR [47]. However, ica operon is not present in all S. aureus strains 
[51], and therefore, it cannot be used as a general biomarker. There still is a lack of tool in the 
diagnosis of biofilm associated infections. It would be necessary to find either a universal bio-
marker that defines all biofilm species or at least, a biomarker species‐specific detectable in the 
particular case of the biofilm presence.
5. Future strategies to fight against biofilm formation
Nowadays biofilm existence cannot be ignored anymore. Scientist community has to find new 
ways of fighting this bacterial social network as to avoid biofilm formation, or to weaken its 
intrinsic resistance, to disrupt biofilm or to kill bacteria embedded in this structure as detailed 
by Bjarnsholt et al. [121] and summarized in Figure 3.
5.1. Prevention by antiadhesive or anticommunication molecules
Prevention will always be the best strategy to fight against biofilm formation. Moreover, inhib-
iting the biofilm formation, bacteria stay under “planktonic” form and are much more suscepti-
ble to antimicrobial or immune system molecules, and therefore easier to eliminate. Prevention 
has to be used as a prophylactic strategy, especially for devices implant during surgery [121]. 
The idea is to avoid bacterial adhesion on material. As a consequence, some anti‐adhesive sur-
faces are developed to be used in implant manufacturing [122]. For example, titan implants 
Figure 3. Strategies “anti‐S. aureus biofilm.”
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coated with gentamicin showed a local action and a short period release fighting S. aureus 
early infection and decreasing toxic side effect [123]. This strategy could be applied when the 
infection is not endogenous as the antibiotic release will end at some point and that the implant 
turns then again into a perfect bacterial support [121]. To prevent bacterial adhesion, it could 
be interesting to target molecules responsible of initial attachment as adhesins by using neu-
tralizing antibodies [121]. A vaccine was developed based on 4 antigens involved in biofilm 
formation of S. aureus. Its efficiency was proved in chronic osteomyelitis rabbit model but only 
in combination with vancomycin to kill the free bacteria [124]. Inhibition of biofilm develop-
ment could be also based on the use of enzymes degrading biofilm matrix components [121] 
such as DNase which avoid the irreversible attachment step but this strategy does not work 
in in vivo models. Inhibition of biofilm formation could be based on the perturbation of signal 
like the presence of endogenous nitrite or the addition of exogenous nitrite [76] or d‐amino 
acids which disturb the initial attachment or the maturation. Moreover, surfaces impregnated 
with those molecules prevent device‐related infection [125, 126]. Antiadhesive strategies are 
often designed for surfaces supporting an antiadhesive molecule which target and antagonized 
adhesin or other specific attachment molecules [122] avoiding any bacteria adhesion.
To conclude, the conceptualization of molecules interfering with signals responsible for 
 biofilm program induction could be imagined and this could lead to the presence of only 
free‐floating bacteria that are more susceptible to antibiotics.
5.2. Weakening
In case the biofilm prevention fails, other strategies have to be developed. Weakening strate-
gies are based on the idea of avoiding the biofilm properties set up, being efficient only on 
biofilm in formation not on mature biofilm [121]. Targets of this strategy are virulence factors, 
communication molecules or specific metabolic pathway involved in biofilm maturation. In 
S. aureus, Agr quorum‐sensing system and Agr‐regulated PSMs are key controllers of biofilm 
structure. In consequence, they are the perfect targets for vaccines or drugs [28, 127]. RNAIII‐
inhibiting peptide negatively regulates quorum‐sensing response, and in consequence, it can 
reduce S. aureus biofilms in vivo [128].
Molecules interrupting the production or assembly of amyloid fibers could consequently 
destabilize biofilm structure. The compound (‐)‐epi‐gallocatechine gallate (EGCG) used to 
fight against amyloid peptides involved in Alzheimer's and Parkinson's diseases is also active 
to inhibit S. aureus biofilm [53]. Another example is the functional micro‐domains which have 
been discovered in bacterial membranes and their inhibition through the application of zara-
gozic acid avoids biofilm formation [129].
It will be interesting to develop other vaccines or drugs which target virulence factors that 
enhance biofilm formation.
5.3. Biofilm disruption
As for “weakening” strategies, targeting Agr quorum‐sensing system in S. aureus will be 
interesting for triggering disruption [28, 127]. Other molecules have been screened for their 
ability to disperse biofilm. A fatty acid messenger named cis‐2‐decenoic acid produced during 
The Rise of Virulence and Antibiotic Resistance in Staphylococcus aureus202
P. aeruginosa growth has shown a capacity to disperse S. aureus biofilm [130]. D‐amino acids 
trigger biofilm disassembly in affecting amyloid fibers and could be a potential strategy to 
disperse a preformed biofilm [125].
Another target to disrupt biofilm is the matrix, using for example, PIA‐degrading enzymes. 
Two matrix polymers in staphylococcal biofilms poly‐N‐acetylglucosamine and eDNA could 
be targeted for their destruction by dispersin B and DNaseI, respectively. Dispersin succeeded 
in detaching pre‐formed S. epidermidis biofilm but not S. aureus ones, and on the contrary, 
DNaseI induced a disruption of S. aureus structures and not S. epidermidis ones [62]. However, 
nucleases do not impact biofilm‐associated infections [66]. Moreover, bacteriophages are 
known to be involved in biofilm dispersion stage [31]. Therefore, bacteriophages were engi-
neered to produce dispersin B, and biofilm mass reduction was noticed [131, 132].
5.4. Killing
To eradicate a pre‐form biofilm is the last chance and this strategy remains the most dif-
ficult to fathom. Many molecules have been tested but they have to respect many criteria 
like the non‐cytotoxicity and the non‐pro‐inflammatory effects. Promising molecules are 
the “anti‐biofilm” peptides inspired by animal antimicrobial peptides (AMPs) which have 
anti‐inflammatory effects and are efficient to destroy Gram‐positive or Gram‐negative bac-
teria at very low concentrations [73, 133]. They have also shown their ability to act in 
synergy with conventional antibiotics, avoiding the use of too high concentrations of each 
molecule [133].
6. Conclusion
After the revolutionary discovery of antibiotics, the medical community thought that the 
battle against microorganisms was won. However, the fight had just begun as bacteria can 
develop resistant structure named biofilm among other strategies. S. aureus is one of the 
most common bacteria found on human epidermis thus when physical barrier such as 
skin is broken, S. aureus could penetrate and adhere to tissue or medical devices. Many 
S. aureus strains are drug‐resistant (MRSA), and moreover, S. aureus represents the most 
frequent germ responsible of chronic biofilm‐associated infection. The treatment against 
this kind of chronic infection is useless in most cases, especially against MRSA. S. aureus 
is also present in food infection and responsible of intoxication. For all these reasons, 
the understanding of S. aureus biofilm is necessary in order to develop new strategies to 
inhibit biofilm formation and/or to eradicate S. aureus biofilm. Nowadays, more and more 
molecular mechanisms are decrypted: bacterial communication, biofilm formation and 
dispersion. Consequently, new molecules are targeted but so far most of this targeting has 
revealed inefficient in in vivo models. Unfortunately, discoveries on biofilm in general and 
on S. aureus biofilm in particular, represent a drop in the ocean. Bacteria are simple organ-
isms with complex mechanisms. We, scientists and physicians, have to integrate the fact 
that planktonic bacteria only reflect the optimal conditions of a laboratory environment. 
`Biofilm is the real enemy, and it changes the all entire picture. New biofilm models have 
to be developed, especially in vivo models.
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